India Recovers $26.6 Million From Drug Makers Over Price Limits
This article was originally published in PharmAsia News
India's drug-pricing agency says it has recovered $26.6 million from drug makers who sold their wares in unapproved dosages and strengths. The National Pharmaceutical Pricing Authority said it has sent notices to 555 pharmaceuticals accusing them of changing their brands to skirt the government's price caps. Drug makers say any changes they have made were in compliance with rules of the drug controller general of India, which is charged with regulating the quality of drugs. The head of the Indian Pharmaceutical Alliance said the changes made by its members were to improve the efficacy of the drugs. (Click here for more
You may also be interested in...
Royal Philips will make 43,000 medical ventilators by year-end for use in the US and make 2,500 more for the Strategic National Stockpile in a deal with the US government worth $646.7m. See what Philips’ CEO Frans van Houten said about it here.
Pharma manufacturing is operating well below normal levels in India, disrupted by labor absenteeism and supply chain issues amid the ongoing lock-down in the country, though the government is actively engaged in addressing bottlenecks. A speedy recovery is vital not just for domestic supplies.
Moderna is pursuing a single-antigen strategy even though some of its mRNA vaccines have included multiple antigens; the SARS-CoV-2 spike protein likely provides the best antigen for developing immunity against the virus.